

Duke-NUS joins TriNetX to increase clinical trial adoption

02 September 2020 | News

This latest member for TriNetX in Asia will provide the network with access to de-identified data from more than a million patients.



Duke-NUS, the only graduate-entry medical school in Singapore, has joined the US based TriNetX global research network to increase clinical trial adoption and to facilitate better collaboration with other global healthcare organizations (HCOs). This latest member for TriNetX in Asia will provide the network with access to de-identified data from more than a million patients.

"We are looking forward to exploring the range of capabilities that TriNetX provides," said Prof. Marcus Ong Eng Hock, Senior Consultant and Clinician Scientist at Duke-NUS. "We plan on taking advantage of the multiple use cases the TriNetX platform offers and we are excited by the opportunity to contribute to the growth of global clinical research."

Duke-NUS was established as a landmark collaboration between Duke University School of Medicine and the National University of Singapore (NUS), two world-ranking institutions of higher education.

The main objective of the collaboration is to provide innovative education and impactful research to enhance the practice of medicine in Singapore. Duke-NUS has five signature research programs: cancer and stem cell biology, neuroscience and behavioral disorders, emerging infectious diseases, cardiovascular and metabolic disorders, and health services and systems research.

"We chose TriNetX to help us further our mission because of their well-established network, their user-friendly technology, and their strong support of their academic partners," said Prof. Marcus Ong Eng Hock.